Public description
Company overview
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases. The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources. We are advancing multiple investigational approaches across the diverse spectrum of lung cancer, informed by the needs and experiences of patients and the broader lung cancer community. Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. We approach the root causes of cancer treatment failure – cancer heterogeneity and interindividual variability – through innovative therapeutic modalities with the aim to expand treatment options for patients. Infectious diseases rank among the leading causes of death globally and remain a significant area of BioNTech’s work. Our goal is to advance the development of innovative vaccines and therapeutics targeting viruses, bacteria and parasites for high medical need indications. Most people think of lung cancer as one disease. We often talk about diseases in the singular. It makes complex topics easier to discuss, but it can also obscure important differences – especially in cancer. We take a closer look at these differences to push science further for people with lung cancer. Find the latest news and background information about BioNTech. Learn more about our company, Website: https://www.biontech.com/us/en/home.html Source: Company site
About
Company overview
The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources. At BioNTech, we are dedicated to improving the health of people worldwide by harnessing the full potential of the human immune system to develop drugs for diseases with high or unmet medical needs. In pursuit of our vision, we are focused on oncology and medicines against a range of infectious diseases. We aim to create long-term value for people and society by pioneering the next generation of immunotherapies and vaccines. With our key capabilities in immunology, deep genomics, and artificial intelligence, we believe we are well-positioned to do so. As a global biotechnology company, our fully-integrated model encompasses scientific groundwork, translational drug discovery, clinical development, GMP manufacturing and commercialization. With our patient-centric treatment approaches we want to become a biotechnological leader in oncology and infectious diseases. Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. We approach the root causes of cancer treatment fail
BioNTech
Company · Subject
| Schema | Name | Relation |
|---|---|---|
| Company | BioNTech | Subject |
